Abstract

This work aimed at developing and validating a rapid, sensitive, and robust method of liquid chromatography with high-resolution mass spectrometry (LC–HRMS) in parallel reaction monitoring (PRM) mode for apixaban quantification in dried plasma spots (DPSs) with a simple extraction procedure. A 25 µL sample of human plasma was placed onto Whatman 903 Protein Saver Cards and allowed to dry; 3.2 mm diameter disks were cut out from DPSs using a puncher, and 100 µL of a working internal standard solution was added to each sample. After this, they were vortexed on a shaker for 15 min at 800 rpm and 40 °C and quick centrifugation (10,000× g, 10 s), and then the extracts were transferred into a 300 µL vial for LC–HRMS. Data were acquired in PRM mode via detection of all target product ions with 10 ppm tolerance. Total analysis time was 5 min. The LC–HRMS method was validated for the 10–400 ng/mL range with R2 > 0.99. Within this range, intra- and interday variability of precision and accuracy was <10%, and recovery was 69.7–85.1%. Apixaban was stable after brief storage at room temperature, and at 4 °C for up to a month. The method development and validation results proved that this LC–HRMS assay of apixaban in DPSs is selective and robust.

Highlights

  • Apixaban is a new-generation oral anticoagulant drug [1]

  • Apixaban is a direct inhibitor of the active site of factor Xa with high selectivity vis-à-vis other coagulation proteases and structurally linked enzymes involved in fibrinolysis and digestion [4]

  • Human plasma is the most commonly used biological fluid for drug assays, and several methods have been developed for apixaban quantitation in human plasma by tandem mass spectrometry with liquid chromatography (LC–MS/MS) [6,9,10,11,12,13,14,15]

Read more

Summary

Introduction

Apixaban is a new-generation oral anticoagulant drug [1]. Apixaban has no direct effect on platelet congestion but indirectly inhibits platelet congestion caused by thrombin. By inhibiting factor Xa, apixaban prevents thrombin formation and thrombus growth [5]. Apixaban is a substrate for P-glycoprotein and may engage in drug interactions [6]. How this drug can be optimally used in specific clinical situations is not clear [7]. An effective and efficient assay of apixaban may help to control the concentration of this drug, especially in rare cases of clinically significant drug interactions or in other special situations [8]. Human plasma is the most commonly used biological fluid for drug assays, and several methods have been developed for apixaban quantitation in human plasma by tandem mass spectrometry with liquid chromatography (LC–MS/MS) [6,9,10,11,12,13,14,15]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call